Gout patients frequently have a number of comorbidities, including obesity, hypertension, high serum lipid and cholesterol levels, kidney disease, diabetes, and cardiovascular disease. [2,7,19–21] Due ...
Credit: Shutterstock. The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum ...
Bone erosion in patients with gout and tophi was associated with tophi duration, drinking history, ulceration, and serum creatinine levels. Bone erosion in patients with gout and tophi was associated ...
In one of these studies, the new product, called AR882 for the time being, reduced serum urate by 40% to 60% in dose-dependent fashion over a 12-week treatment period, whereas a placebo group showed ...
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback